STOCK TITAN

Fractyl Health details $515K in conditional severance

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K/A

Rhea-AI Filing Summary

Fractyl Health, Inc. (GUTS) disclosed separation and consulting terms for Jay Caplan, who retired as president and chief product officer effective October 30, 2026. Conditional cash severance is $515,000, equal to 12 months of annual base salary, subject to the agreement taking effect after the applicable revocation period and Caplan’s continued compliance with restrictive covenant obligations; the company will also provide up to 12 months of paid COBRA continuation coverage. His consulting agreement, effective October 31, 2026, provides an initial six-month term at $250.00 per hour, up to 40 hours per month, for transition services.

Filing Explained

The amendment adds that no minimum consulting services are guaranteed and the agreement may be ended on 30 days’ notice by Fractyl or 60 days’ notice by Caplan, so the six-month term does not commit Fractyl to six months of consulting fees.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Separation cash payments $515,000 Equal to 12 months of annual base salary; subject to the Separation Agreement’s conditions
Salary period 12 months Annual base salary used to calculate separation cash payments
COBRA continuation coverage Up to 12 months Company-paid coverage under the Separation Agreement
Consulting rate $250.00 per hour For time spent performing consulting services
Consulting hours cap 40 hours per month Maximum hours under the consulting agreement
Initial consulting term 6 months From the agreement’s October 31, 2026 effective date
Company termination notice 30 days Prior written notice for termination for convenience
Caplan termination notice 60 days Prior written notice
COBRA continuation coverage regulatory
"up to 12 months of Company-paid COBRA continuation coverage"
restrictive covenant obligations regulatory
"continued compliance with his restrictive covenant obligations"
revocation period regulatory
"following expiration of the applicable revocation period"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What severance did Fractyl Health (GUTS) agree to pay Jay Caplan?

The Separation Agreement provides $515,000 in cash payments, equal to 12 months of annual base salary, plus up to 12 months of company-paid COBRA continuation coverage. Both are subject to the agreement becoming effective after the applicable revocation period and Caplan’s continued compliance with restrictive covenant obligations.

Can Fractyl Health (GUTS) or Jay Caplan terminate the consulting agreement early?

The company may terminate for convenience on 30 days’ prior written notice, while Caplan may terminate on 60 days’ prior written notice. The agreement does not guarantee any minimum level of services.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001572616true00015726162026-10-212026-10-21

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K/A
(Amendment No. 1)

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 21, 2026

 

 

Fractyl Health, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-41942

27-3553477

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

3 Van de Graaff Drive

Suite 200

 

Burlington, Massachusetts

 

01803

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (781) 902-8800

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.00001 par value per share

 

GUTS

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


Explanatory Note

This Amendment No. 1 on Form 8-K/A (this “Amendment”) amends the Current Report on Form 8-K filed by Fractyl Health, Inc. (the “Company”) with the Securities and Exchange Commission on October 22, 2026 (the “Original Form 8-K”), which reported, among other things, the retirement of Jay Caplan as the Company’s President and Chief Product Officer. This Amendment is being filed to disclose the material terms of the Separation Agreement and Release (the “Separation Agreement”) and the consulting agreement (the “Consulting Agreement”) entered into by Mr. Caplan and the Company following the filing of the Original Form 8-K, and to file the Separation Agreement and the Consulting Agreement as exhibits. Except as set forth herein, this Amendment does not amend, modify or update any other disclosure contained in the Original Form 8-K, and this Amendment should be read in conjunction with the Original Form 8-K.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Retirement of Executive Officer

As previously disclosed on October 22, 2026, effective as of October 30, 2026, Jay Caplan retired from the Company as its President and Chief Product Officer.

 

In connection with Mr. Caplan’s retirement, on November 16, 2026, Mr. Caplan and the Company entered into the Separation Agreement. Subject to the Separation Agreement becoming effective following expiration of the applicable revocation period and Mr. Caplan’s continued compliance with his restrictive covenant obligations, Mr. Caplan will receive (i) cash payments of $515,000, equal to 12 months of his annual base salary, payable in accordance with the Company’s normal payroll schedule and (ii) up to 12 months of Company-paid COBRA continuation coverage. The Separation Agreement includes a release of claims.

 

In addition, on November 19, 2026, Mr. Caplan and the Company entered into the Consulting Agreement, effective as of October 31, 2026, pursuant to which Mr. Caplan will provide consulting services to the Company during this transition for an initial term of six months from the effective date, pursuant to which the Company will pay Mr. Caplan an hourly rate of $250.00 for the time spent performing such services, subject to a cap of 40 hours per month and any withholding required by applicable law. The Consulting Agreement does not guarantee any minimum level of services and may be terminated for convenience by the Company on 30 days’ prior written notice or by Mr. Caplan on 60 days’ prior written notice.

Copies of the Separation Agreement and Consulting Agreement are attached hereto as Exhibit 10.1 and Exhibit 10.2, respectively. The above descriptions of the material terms of the Separation Agreement and Consulting Agreement do not purport to be complete and are qualified in their entirety by reference to the applicable Exhibit.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.

Description

10.1

 

Separation Agreement and Release by and between Fractyl Health, Inc. and Jay Caplan dated November 16, 2026

10.2

 

Consulting Agreement by and between Fractyl Health, Inc. and Jay Caplan effective October 31, 2026

104

Cover Page Interactive Data File (embedded within the inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Fractyl Health, Inc.

 

 

 

 

Date:

November 19, 2026

By:

/s/ Harith Rajagopalan

 

 

 

Harith Rajagopalan, M.D., Ph.D.
Co-Founder, President, Chief Executive Officer and Director
(Principal Executive Officer)

 


Filing Exhibits & Attachments

3 documents

Keep reading